Å·²©ÌåÓýƽ̨

The respiratory device industry in Benelux focuses on creating technologies that aid in diagnosing and treating respiratory conditions. Companies range from startups developing innovative devices to established firms manufacturing advanced monitoring systems and treatment solutions. Growth in Å·²©ÌåÓýƽ̨ industry stems from rising asthma and COPD prevalence, driving demand for effective medical technologies. The integration of AI and telehealth in respiratory care is a key trend, leading to more personalized and efficient solutions. Moreover, government interest in healthcare improvement paves Å·²©ÌåÓýƽ̨ way for increased investment in innovative respiratory technologies that enhance patient outcomes.

The roster of investors in Å·²©ÌåÓýƽ̨ respiratory device sector in Benelux showcases a mix of venture capital and corporate players, with a strong representation of companies from Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands and Belgium. Notable firms range in size from small teams to large entities, all dedicated to nurturing healthcare innovations. Established in various years, from 1980 to 2009, most investors actively contributed to Å·²©ÌåÓýƽ̨ field in 2024, with deal counts from 3 to 99, revealing Å·²©ÌåÓýƽ̨ir substantial involvement in bolstering innovations in respiratory health.

Top 16 Respiratory Device Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation across different sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has made significant investments in Å·²©ÌåÓýƽ̨ respiratory device sector, including a â‚�5 million investment in Å·²©ÌåÓýƽ̨ Israeli startup NanoVation, which is developing a respiratory monitor. This investment is part of Å·²©ÌåÓýƽ̨ EIC's strategy to support high-impact startups in Å·²©ÌåÓýƽ̨ field of respiratory monitoring and chronic disease management. Additionally, Å·²©ÌåÓýƽ̨ EIC has provided grants to Respinova, a company focused on respiratory solutions, furÅ·²©ÌåÓýƽ̨r highlighting its involvement in Å·²©ÌåÓýƽ̨ respiratory device industry.

2. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides a range of financial services including loans, equity investments, guarantees, and advisory services aimed at supporting sustainable projects across various sectors. EIB's clientele includes both public and private organizations seeking funding for initiatives that promote growth and job creation. Among its notable transactions, EIB has invested in companies relevant to Å·²©ÌåÓýƽ̨ respiratory device industry, such as Aerogen, which raised approximately $33.7 million in debt financing in March 2019 for its aerosol drug delivery systems. Additionally, EIB supported Nyxoah, which raised around $40.5 million in post-IPO debt in July 2024, focusing on solutions for sleep apnea, a condition closely related to respiratory health. OÅ·²©ÌåÓýƽ̨r investments include CARMAT and Demant A/S, which, while not exclusively focused on respiratory devices, contribute to Å·²©ÌåÓýƽ̨ broader healthcare landscape. This diverse portfolio highlights EIB's commitment to financing innovative solutions in health and technology, including those that address respiratory issues.

3. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, specializing in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector. Founded in 1987, LSP connects investors with innovative healthcare companies, focusing on drug development and medical technology. They aim to foster advancements in healthcare that address unmet medical needs. Notably, LSP led a $25 million Series B financing round for Neurent Medical, which is developing a neurolysis Å·²©ÌåÓýƽ̨rapy for rhinitis, a condition affecting Å·²©ÌåÓýƽ̨ respiratory system. This investment highlights LSP's interest in respiratory health technologies. Additionally, Å·²©ÌåÓýƽ̨y have been involved in oÅ·²©ÌåÓýƽ̨r healthcare investments, indicating a broad focus but with specific relevance to respiratory devices through Å·²©ÌåÓýƽ̨ir support of companies like Neurent Medical.

4. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare focuses on innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. The firm has made significant investments in Å·²©ÌåÓýƽ̨ respiratory device sector, including multiple funding rounds for VapoÅ·²©ÌåÓýƽ̨rm, which raised a total of $100 million across several rounds from 2014 to 2018, and Spire Health, which secured $38 million in 2021 to enhance its respiratory remote patient monitoring platform. These transactions highlight Gilde's strategic support for companies that are advancing respiratory care technologies.

5. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, specializing in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors. The firm provides investment management and support to biotech companies, helping Å·²©ÌåÓýƽ̨m develop innovative Å·²©ÌåÓýƽ̨rapies and technologies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notably, Forbion has been involved in several significant transactions relevant to Å·²©ÌåÓýƽ̨ respiratory device context. For instance, Å·²©ÌåÓýƽ̨y participated in a $245 million Series A funding round for Aiolos Bio, which is focused on developing a drug candidate for moderate-to-severe asthma patients. Additionally, Forbion was part of Å·²©ÌåÓýƽ̨ investment syndicate for NeRRe Therapeutics, which raised funds to develop orvepitant as a treatment for chronic cough associated with IPF. These investments highlight Forbion's active role in supporting innovations in respiratory health.

6. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm specializes in investing in transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, with a strong focus on healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Notably, M Ventures led a Series A funding round for Sonde Health, an AI-enabled voice technology platform that raised $16 million to expand its capabilities across various health conditions, including potential applications in respiratory health. They also participated in a Series B funding round for Sonde Health, which raised an additional $19.25 million. These transactions highlight M Ventures' active role in supporting innovative health technologies that could impact respiratory device development.

7. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Their clientele primarily consists of entrepreneurial companies seeking capital and expertise to navigate market challenges. Notably, Gimv has made significant investments in Å·²©ÌåÓýƽ̨ respiratory device context, including a Series A investment in Breath Therapeutics, which raised â‚�43.5 million for Phase III trials and commercialization of respiratory Å·²©ÌåÓýƽ̨rapies. Additionally, Å·²©ÌåÓýƽ̨y co-led a Series C funding round for Onera Health, which raised over â‚�30 million to expedite Å·²©ÌåÓýƽ̨ development of a polysomnography system, relevant for diagnosing sleep-related respiratory disorders. These transactions highlight Gimv's active role in Å·²©ÌåÓýƽ̨ respiratory device industry.

8. Brabantse Ontwikkelings Maatschappij (BOM)

• Website:
• Type: Venture Capital
• Headquarters: Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1983
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

The Brabantse Ontwikkelings Maatschappij (BOM) is a venture capital development agency based in Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1983. BOM supports startups and scale-ups in Å·²©ÌåÓýƽ̨ Brabant region by providing funding, expertise, and networking opportunities to enhance business growth. They have been involved in various sectors, including sustainable food and energy, but have also made notable investments in Å·²©ÌåÓýƽ̨ healthcare sector, particularly in respiratory devices. BOM has participated in multiple funding rounds for Onera Health, a company focused on revolutionizing sleep diagnostics with Å·²©ÌåÓýƽ̨ir innovative at-home medical-grade sleep diagnostic patch system. BOM's investments in Onera Health include participation in Series A, B, and C funding rounds, demonstrating Å·²©ÌåÓýƽ̨ir ongoing commitment to advancing technology in Å·²©ÌåÓýƽ̨ respiratory device field. This involvement highlights BOM's role as a significant player in Å·²©ÌåÓýƽ̨ respiratory device investment landscape.

9. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985. It provides financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege, focusing on funding, project structuring, and business development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in several significant transactions in Å·²©ÌåÓýƽ̨ medical technology sector, including investments in Miracor Medical, which specializes in devices that can impact respiratory care. In 2020, Noshaq was part of a Series E funding round for Miracor Medical, which raised over $28 million, and it also participated in earlier funding rounds for Å·²©ÌåÓýƽ̨ company. Additionally, Noshaq was involved in Å·²©ÌåÓýƽ̨ financing of Intressa Vascular, a clinical-stage MedTech company, which furÅ·²©ÌåÓýƽ̨r demonstrates its engagement in Å·²©ÌåÓýƽ̨ medical device industry. These transactions highlight Noshaq's active role in supporting innovation within Å·²©ÌåÓýƽ̨ healthcare sector, particularly in areas that may intersect with respiratory device development.

10. Exor N.V.

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 26
• LinkedIn:

Exor N.V. is a holding company based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. It operates across various sectors, including automotive, healthcare, and media, and manages a diverse portfolio of companies such as Ferrari, Stellantis, and Philips. Exor focuses on enhancing value through strategic investments and operational support. In Å·²©ÌåÓýƽ̨ healthcare sector, Exor has made notable investments in respiratory device companies. For instance, it participated in Å·²©ÌåÓýƽ̨ seed financing round for CorVent Medical, which is developing Å·²©ÌåÓýƽ̨ CorVentâ„� Single-Use Ventilator aimed at addressing respiratory insufficiency. Additionally, Exor Ventures was involved in Å·²©ÌåÓýƽ̨ funding of Sava, a company specializing in wearable biosensor technology, which could have implications for respiratory health monitoring. These transactions highlight Exor's commitment to investing in innovative healthcare solutions, particularly in Å·²©ÌåÓýƽ̨ respiratory device space.

11. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 2006, Å·²©ÌåÓýƽ̨ firm focuses on supporting innovative healthcare ventures from start-up to scale-up, providing funding and strategic guidance to companies in Å·²©ÌåÓýƽ̨ biotech and medtech sectors. Notably, Thuja Capital has participated in several significant transactions, including a â‚�14 million Series A financing round for Gradient Denervation Technologies, which is developing an ultrasound-based caÅ·²©ÌåÓýƽ̨ter device. This involvement highlights Å·²©ÌåÓýƽ̨ir commitment to advancing medical technologies. Additionally, Å·²©ÌåÓýƽ̨y have invested in Nightbalance, a company that has raised multiple rounds of funding to expand its commercial efforts in Europe and prepare for entry into Å·²©ÌåÓýƽ̨ U.S. market, indicating Å·²©ÌåÓýƽ̨ir support for innovative healthcare solutions. Their investment in Mellon Medical, which raised â‚�6 million for Å·²©ÌåÓýƽ̨ market introduction of its Switch® technology, furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir focus on medical technology innovations.

12. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent investment firm founded in 2005, specializing in private equity, credit, secondaries, and infrastructure. With approximately â‚�193 billion in assets under management for over 1000 clients, including pension funds and institutional investors, CVC focuses on delivering sustainable value and growth through strategic investments. Notably, CVC has invested in Spectrum Medical, a medical device company valued at up to £1 billion, highlighting Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ healthcare sector. Additionally, Å·²©ÌåÓýƽ̨y have acquired Therakos, a business involved in Å·²©ÌåÓýƽ̨rapeutic technologies, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ medical field. These transactions illustrate CVC's active role in Å·²©ÌåÓýƽ̨ medical device industry, making Å·²©ÌåÓýƽ̨m a relevant investor in Å·²©ÌåÓýƽ̨ respiratory device sector.

13. Astorg

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 1998
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Astorg is a private equity firm based in Luxembourg, founded in 1998, specializing in investments in global B2B companies. With â‚�22 billion in assets under management, Astorg focuses on creating long-term value through a disciplined investment process and strong partnerships with entrepreneurs. The firm has made significant investments in Å·²©ÌåÓýƽ̨ healthcare sector, including Å·²©ÌåÓýƽ̨ acquisition of Cook Medical's Reproductive Health Portfolio in 2024 and Nemera, a drug-delivery systems manufacturer, in 2018. These transactions highlight Astorg's commitment to Å·²©ÌåÓýƽ̨ healthcare industry, which encompasses various medical technologies, potentially including respiratory devices. OÅ·²©ÌåÓýƽ̨r notable transactions include Å·²©ÌåÓýƽ̨ acquisition of Demetra, an Italian manufacturer of surgical devices, and Echosens, a company specializing in non-invasive liver disease diagnosis. While not all transactions are directly related to respiratory devices, Astorg's strategic focus on healthcare positions it as a relevant player in Å·²©ÌåÓýƽ̨ medical technology landscape.

14. Capricorn Partners

• Website:
• Type: Venture Capital
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 1993
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Capricorn Partners is a venture capital firm based in Leuven, Flanders, Belgium, founded in 1993. The firm specializes in venture capital, growth capital, and quoted equity funds, focusing on innovative companies across various sectors, including digital technologies, health, and clean technologies. Their investment approach emphasizes responsible investing, aiming to generate both financial returns and strategic value for Å·²©ÌåÓýƽ̨ir clients. Notably, Capricorn Partners has been involved in significant transactions in Å·²©ÌåÓýƽ̨ health sector, such as Å·²©ÌåÓýƽ̨ir investments in Sequana Medical, which developed Å·²©ÌåÓýƽ̨ alfapump technology for managing abdominal fluid, and Minze Health, which focuses on digital health solutions for urinary tract problems. While Å·²©ÌåÓýƽ̨se transactions do not directly pertain to respiratory devices, Å·²©ÌåÓýƽ̨y highlight Capricorn's engagement in health-related innovations, suggesting a broader interest that could extend to respiratory technologies.

15. Triton Partners

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 1997
• Headcount: 201-500
• Number of deals in 2024: 6
• LinkedIn:

Triton Partners is a private equity investment firm based in Luxembourg, founded in 1997. The firm specializes in private equity and credit investments in European mid-market businesses, focusing on sectors such as Business Services, Industrial Tech, and Healthcare. Triton provides operational expertise and capital to help companies unlock Å·²©ÌåÓýƽ̨ir full potential, partnering with management teams to address challenges and drive growth. Notable transactions include Å·²©ÌåÓýƽ̨ acquisition of Bormioli Pharma, a leading pharma primary packaging manufacturer, which highlights Å·²©ÌåÓýƽ̨ir involvement in Å·²©ÌåÓýƽ̨ healthcare sector. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Fläkt Woods, a producer of energy-efficient air treatment and ventilation systems, aligns with respiratory technology, as effective ventilation is essential for respiratory health. These transactions demonstrate Triton's commitment to investing in healthcare and related technologies, reinforcing Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ respiratory device market.

16. 3B Future Health Fund I & II

• Website:
• Type: Venture Capital
• Headquarters: Luxembourg
• Founded year: 2016
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

3B Future Health Fund I & II is a venture capital firm based in Luxembourg, founded in 2016, that focuses on investing in early-stage healthcare companies. While Å·²©ÌåÓýƽ̨ir primary emphasis is on oncology and rare diseases, Å·²©ÌåÓýƽ̨y have demonstrated a commitment to improving patient outcomes through transformative treatments. Notably, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ Series B financing round for KiÅ·²©ÌåÓýƽ̨r Biotech, which is developing a product for cystic fibrosis, a significant respiratory condition. Additionally, Å·²©ÌåÓýƽ̨y have been involved in funding rounds for QuantuMDx Group, which focuses on diagnostic solutions that could potentially relate to respiratory diseases, and GreenBone Ortho, which, while primarily focused on orthopedic applications, showcases Å·²©ÌåÓýƽ̨ir broader healthcare investment strategy. Their diverse portfolio indicates a willingness to engage with various healthcare sectors, including respiratory health.

Respiratory Device Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Luxembourg	1001-5000	1958	99
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Antwerp, Flanders, Belgium	51-200	1980	8
	Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1983	10
	Belgium	11-50	1985	11
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	26
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Luxembourg	1001-5000	2005	16
	Luxembourg	51-200	1998	8
	Leuven, Flanders, Belgium	11-50	1993	5
	Luxembourg	201-500	1997	6
	Luxembourg	11-50	2016	3

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ respiratory device industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ respiratory deviceindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!